BioSpace
By BioSpace
Listen to a podcast, please open Podcast Republic app. Available on Google Play Store and Apple App Store.
Image by BioSpace
Category: Life Sciences
Open in Apple Podcasts
Open RSS feed
Open Website
Rate for this podcast
Subscribers: 0
Reviews: 0
Episodes: 46
Description
Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.
| Episode | Date |
|---|---|
|
Bayer Layoffs, a Big Alzheimer’s Deal and ASGCT Wrap
|
May 15, 2024 |
|
Women's Health: Where Politics and Science Meet
|
May 09, 2024 |
|
ASGCT, Adcomm for Lilly’s Donanemab, Vertex Vs. Bluebird
|
May 08, 2024 |
|
BioSpace Heads to #ASGCT, Along with Thousands in Cell and Gene Therapy
|
May 03, 2024 |
|
The IRA, BMS’ Big Cuts, First WHIM Approval
|
May 01, 2024 |
|
Where Do We Go From Here? The Future of Women's Health
|
Apr 25, 2024 |
|
Sanofi Layoffs, CAR-T Warnings and a New GLP-1 Player
|
Apr 24, 2024 |
|
Amylyx and ALS, Continued ADC Excitement, Dire Drug Shortages
|
Apr 17, 2024 |
|
It's a Design Problem: Women and Clinical Trials
|
Apr 11, 2024 |
|
Alphabet Soup: AACR and ACC Dominate Headlines This Week
|
Apr 10, 2024 |
|
Did WuXi Make a Whoopsie? US-China R&D Relations in Limbo
|
Apr 03, 2024 |
|
Will the IRA’s Focus on the Pharmaceutical Industry Hurt the World’s Healthcare System Instead of Helping Patients?
|
Mar 28, 2024 |
|
Bayer’s sweeping executive cuts, Wegovy’s expanding reach
|
Mar 27, 2024 |
|
Money talk: Salary trends and raises
|
Mar 21, 2024 |
|
Historic approval for MASH, CAR-Ts in the spotlight
|
Mar 20, 2024 |
|
The unintended consequences of small molecules
|
Mar 14, 2024 |
|
The skinny on weight loss, donanemab and the State of the Union
|
Mar 13, 2024 |
|
The ABCs of ADCs: Why antibody-drug conjugates are so hot right now
|
Mar 06, 2024 |
|
The gap is where the pain is: Drug pricing and patient costs
|
Feb 29, 2024 |
|
Sweet succession: Gonzalez, patent thickets and his triumph over biosimilars
|
Feb 28, 2024 |
|
Iovance wins with Amtagvi and the ADC train chugs on
|
Feb 21, 2024 |
|
Eyes on the prize: Novo buys Catalent
|
Feb 14, 2024 |
|
Balancing act: Patient access and innovation
|
Feb 07, 2024 |
|
Keep calm and CAR-T on?
|
Jan 31, 2024 |
|
What can biopharma expect from the job market?
|
Jan 25, 2024 |
|
Grab an umbrella, it's raining IPOs!
|
Jan 24, 2024 |
|
Optimistic, but for how long? Our big takeaways from #JPM2024
|
Jan 17, 2024 |
|
On the ground at #JPM2024 - Day 3 highlights
|
Jan 10, 2024 |
|
On the ground at #JPM2024 - Day 2 highlights
|
Jan 10, 2024 |
|
On the ground at #JPM2024 - Day 1 highlights
|
Jan 08, 2024 |
|
Alternative funding strategies to discuss at JPM with Halia Therapeutics, the ADDF and Triumvira Immunologics
|
Jan 04, 2024 |
|
The top life sciences startups to watch this year
|
Jan 03, 2024 |
|
What VCs look for when investing with MPM Capital, Endeavor Venture Fund and Two Bear Capital
|
Dec 21, 2023 |
|
Every move you make: Biopharma industry under heavy scrutiny
|
Dec 20, 2023 |
|
What VCs really think of the market right now with MPM Capital, Endeavor Venture Fund and Two Bear Capital
|
Dec 14, 2023 |
|
Major FDA approvals for Vertex/CRISPR; bluebird gets black box warning and price scrutiny
|
Dec 13, 2023 |
|
Fast and furious evolution: How to ensure AI is catalyst for positive societal change with Microsoft and IQVIA
|
Dec 12, 2023 |
|
Integrating AI in life sciences to change employee behavior with Microsoft and IQVIA
|
Dec 07, 2023 |
|
GLP-1 and ADC rollercoasters pick up speed
|
Dec 06, 2023 |
|
Artificial Intelligence, Part 3: Improving Communication to Impact Patient Behavior
|
Dec 05, 2023 |
|
Artificial Intelligence, Part 2: Human Interaction, Liability, and Patient Safety
|
Nov 30, 2023 |
|
Deals, Dupixent and GLP-1 drug shortages
|
Nov 29, 2023 |
|
First ever CRISPR gene therapy approval: What happens next?
|
Nov 21, 2023 |
|
Artificial Intelligence, Part 1: Bias, Access, ROI, Potential Success and Failure
|
Nov 16, 2023 |
|
Zepbound vs Wegovy: A two horse race
|
Nov 15, 2023 |
|
Q3 earnings recap: Winners, losers & surprises
|
Nov 08, 2023 |